A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and
Pediatric Subjects with Previously Treated NTRK Fusion
The purpose of the study, in phase 1, is to test the safety of a study drug called LOXO-195 (study drug) in men, women and children with previously treated NTRK Fusion cancers.
Previously treated NTRK fusion cancer
1. Recurrent or metastatic solid tumors
2. Adequate organ function
3. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. If your disease gets worse during the study, you may be able to remain on the study for additional treatments if the investigator thinks the study drug can continue to benefit you. After the last dose of the study drug, participants will perform a 28 day post treatment follow-up. Thereafter, they will contacted by phone every 12 weeks until the end of the study.
Knight Clinical Trials Information Line